Evidence map›Paper›PMID 37040372›Full record

Trial reportPloS one2023

Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: A randomised, double-blind, placebo-controlled, crossover trial.

Sophia G Connor, Timothy J Fairchild, Yvonne C Learmonth, Kelly Beer, Ian Cooper, Glenn Boardman, Shaun Y M Teo, Behnaz Shatahmasseb, Rui Zhang, Krystyne Hiscock and 3 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Creatine monohydrate supplementation for older adults and clinical populations.Journal of the International Society of Sports Nutrition · 2025
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Sophia G ConnorRoyal Perth Hospital, Perth, Western Australia, Australia.ORCID 0000-0003-3884-4084
Timothy J FairchildCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Yvonne C LearmonthCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Kelly BeerCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Ian CooperCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Glenn BoardmanResearch Development Unit, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Shaun Y M TeoCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.ORCID 0000-0002-9496-813X
Behnaz ShatahmassebCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Rui ZhangDepartment of Clinical Biochemistry, Pharmacology and Toxicology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, WA, Australia.
Krystyne HiscockAffinity Clinical Research, Nedlands, Western Australia, Australia.
Jerome D CoudertCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.ORCID 0000-0001-6081-8494
Bu B YeapDepartment of Endocrinology and Diabetes, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Merrilee NeedhamCentre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Murdoch University · AUFiona Stanley Hospital · AUQueen Elizabeth II Medical Centre · AURoyal Perth Hospital · AUThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInclusion body myositis (IBM) is the most commonly acquired skeletal muscle disease of older adults involving both autoimmune attack and muscle degeneration. As exercise training can improve outcomes in IBM, this study assessed whether a combination of testosterone supplementation and exercise training would improve muscle strength, physical function and quality of life in men affected by IBM, more than exercise alone.

methodsThis pilot study was a single site randomised, double-blind, placebo-controlled, crossover study. Testosterone (exercise and testosterone cream) and placebo (exercise and placebo cream) were each delivered for 12 weeks, with a two-week wash-out between the two periods. The primary outcome measure was improvement in quadriceps isokinetic muscle strength. Secondary outcomes included assessment of isokinetic peak flexion force, walk capacity and patient reported outcomes, and other tests, comparing results between the placebo and testosterone arms. A 12-month Open Label Extension (OLE) was offered using the same outcome measures collected at 6 and 12-months.

results14 men completed the trial. There were no significant improvements in quadriceps extension strength or lean body mass, nor any of the secondary outcomes. Improvement in the RAND Short Form 36 patient reported outcome questionnaire 'emotional wellbeing' sub-category was reported during the testosterone arm compared to the placebo arm (mean difference [95% CI]: 6.0 points, [95% CI 1.7,10.3]). The OLE demonstrated relative disease stability over the 12-month period but with a higher number of testosterone-related adverse events.

conclusionsAdding testosterone supplementation to exercise training did not significantly improve muscle strength or physical function over a 12-week intervention period, compared to exercise alone. However, the combination improved emotional well-being over this period, and relative stabilisation of disease was found during the 12-month OLE. A longer duration trial involving a larger group of participants is warranted.

Indexed as

Myositis, Inclusion BodyTestosteroneAgedCross-Over StudiesExerciseHumansMaleMuscle StrengthPilot ProjectsQuality of LifeTestosterone

Identifiers

PMID37040372
PMCPMC10089314
OpenAlexW4364351724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.